Executives On The Move: Exits From Takeda Vaccines And Novartis Institutes To CMO Positions And Board Changes At Merck & Co.
Takeda Vaccines VP switches to cancer immunotherapy and vaccine company Bavarian Nordic and Novartis Institutes exec moves to molecular medicines firm Boston Pharmaceuticals, each in the CMO position. Meanwhile, Merck & Co will add a scientific and a strategic expert to its board.
You may also be interested in...
Executives On The Move: BMS Taps Barclays Exec For Strategy Spot, Epizyme Selects Science Chief And A Board Election At ADC Therapeutics
Bristol-Myers Squibb taps Barclays chair of global life sciences as it EVP, strategy and business development, and cancer therapeutics firm Epizyme Inc. selects a chief scientific officer. At ADC Therapeutics, an oncology drug development company, a new chairman is elected.
Executives On The Move: Global Aesthetics Head Exits Allergan for Merz, C-Level Commercial Changes at Flexion And Karyopharm
Merz Pharma Group’s Merz Aesthetics welcomes former Allergan exec as new chief scientific officer. Meanwhile, a chief commercial officer is appointed at Flexion Therapeutics, developer of treatments for musculoskeletal conditions, and at Karyopharm Therapeutics, an oncology-focused pharma.
Executives On The Move: UCB Announces Future Financial Leadership Change And Analytics Experience for Corbus Pharma
Corbus Pharmaceuticals, developer of therapeutics for inflammatory and fibrotic diseases, hires EMD Serono exec as head of commercial ops and analytics. Also, multinational biopharma UCB to have a new CFO in July.